DNA vaccine against zika performs well in tests on mice
The vaccine is being developed by researchers in Brazil. The results of preclinical trials are published in the journal Frontiers in Immunology.
The vaccine is being developed by researchers in Brazil. The results of preclinical trials are published in the journal Frontiers in Immunology.
Highlights monthly webcast presentations for CE credit by FDA scientists from across agency on their cutting-edge scientific research
Scientists are harnessing cells to make new types of materials that can grow, repair themselves and even respond to their environment. These solid “engineered living…
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association’s (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in…
APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), ARCHES trial, enzalutamide, Delta-like ligand 3 (DLL3), LuPSMA.
Nonsense-mediated RNA decay, or NMD, is an evolutionarily conserved molecular mechanism in which potentially defective messenger RNAs, or mRNAs (genetic material that instructs the body…
Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as…
Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial’s design…
**ECCMID has now changed name to ESCMID Global, please credit ESCMID Global Congress (formerly ECCMID, Barcelona, Spain, 27-30 April) in all future stories** With artificial…
CVS Health is lowering its guidance for the year after a first-quarter miss on both profit and revenue. | The company posted $1.1 billion in…
APCCC 2024, Radioligand Therapy, Dosing of Radioligand Therapy, Dosing of Radioligand Therapy in Special Situations And/or Toxicity, 177Lu-PSMA, VISION trial, Lu-PSMA therapy, Lu-PSMA I&T, ENZA-p…